DefinitionThis section has been translated automatically.
Highly selective, recombinant (human-mouse), humanized, IgG1 antibody against the alpha chain (= Tac; = CD 25) of the human IL-2 receptor.
Pharmacodynamics (Effect)This section has been translated automatically.
Highly selective binding of daclizumab antibodies to the alpha chain of interleukin-2 receptors on activated T cells. This inhibits the proliferation of activated T-cells and thus also interleukin-2 controlled inflammatory processes and rejection reactions via T-lymphocytes. In the presence of daclizumab the stimulating effect of IL-2 on lymphocytes is reduced.
You might also be interested in
IndicationThis section has been translated automatically.
Approved for the prophylaxis of acute rejection after kidney transplantation in combination with standard therapy including ciclosporin and systemic glucocorticoids.
According to single case reports ( off-label use) well effective in psoriasis vulgaris, pemphigus vulgaris, psoriatic arthritis, graft-versus-host disease, ulcerative colitis, HIV-associated erythrodermia psoriatica.
Dosage and method of useThis section has been translated automatically.
Adults/children: 1 mg/kg bw i.v. in 50 ml sterile NaCl 0.9% solution over 15 minutes. The next application and all further applications are reached in intervals of 14 days each until a total of 5 applications are reached.
Undesirable effectsThis section has been translated automatically.
According to approval studies, overall few side effects compared with placebo. Rare wound healing disorders, pruritus, acne. Side effects more common in children compared to adults: diarrhea (41%), post-operative pain (38%), fever (33%), vomiting (33%), hypertension (28%), pruritus (21%), upper respiratory tract infections (20%) and urinary tract infections (18%).
ContraindicationThis section has been translated automatically.
Pregnancy and lactation (insufficient data available). Hypersensitivity to the active substance or other ingredients of the preparation.
PreparationsThis section has been translated automatically.
Zenapax®
LiteratureThis section has been translated automatically.
- Cather JC et al (2003) Investigational therapies for psoriasis. J Am Acad Dermatol 49: S133-138
- Dichmann S et al (2002) Humanized monoclonal anti-CD25 antibody as a novel therapeutic option in HIV-associated psoriatic erythroderma. J Am Acad Dermatol 47: 635-366
- Gottlieb AB et al (2002) Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 105: 105-116
- Jacobsohn DA (2002) Novel therapeutics for the treatment of graft-versus-host disease. Expert Opinion Investig Drugs 11: 1271-1280
- Lee SJ et al (2004) Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104: 1559-1564
- Linden O (2004) Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab. N Engl J Med 351: 1466-1467
- Nashan B (2005) Antibody induction therapy in renal transplant patients receiving calcineurin inhibitor immunosuppressive regimens: a comparative review. BioDrugs 19: 39-46
- Renkl A et al (2004) A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibody. Br J Dermatol 150: 1220-1222
- Van Assche G (2003) A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. At J Gastroenterol 98: 369-376
Prof. Dr. med. Peter Altmeyer
